MedTrace Logo

Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome

NCT06953661 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-10-15

No results posted yet for this study

Summary

This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.

Conditions

  • Postural Tachycardia Syndrome

Interventions

PROCEDURE

Stellate ganglion block

Patients will receive a SGB

PROCEDURE

Sham injection of saline

Patients will receive a subcutaneous sham injection of saline

DRUG

Ropivacaine

The SGB group will receive ropivacaine 0.5% 10ml

DRUG

Normal saline

The control group will receive normal saline in the sham injection.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-13
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06953661 on ClinicalTrials.gov